Genmab — Juli 2012
-
jeg tror ikke ATP ligger og trader Genmab, det må være på den lange bane
-
Men det må være en rimelig stor spiller der bruger Carnegie
-
vi har hørt tallet 1800 pts helt tilbage for 2011
-
det ville give omkring 120-140 mill dollar totalt
-
og vi ligger vel på 60% af det i omsætning
-
men jeg er usikker på om 1800 pts ikke blot var us pts efter 2-3 kvartaler
-
-
den ser lidt tom ud?
-
-
RITUXAN
(rituximab) revenues from our unconsolidated joint business arrangement were $285 million for the quarter, an increase of 31% year-over-year. As previously disclosed, during the second quarter of 2011 our share of RITUXAN revenues from unconsolidated joint business was reduced by approximately $50 million to reflect our share of damages and interest that might be awarded in relation to an intermediate decision in Genentech, Inc.’s ongoing arbitration with Hoechst GmbH. -
carnegie køber skægt nok ikke idag (endnu). Hvilket gør det til 1 ud af bare 2 handelsdagen indenfor de sidste 50-60 stykker hvor Carnegie ikke har købt
-
H1 2012 (£375 million; +22%)
Growth in the category in the half year was driven by new products Votrient (up 87% to £72 million),
Promacta (up 97% to £57 million) and Arzerra (up 35% to £27 million). Hycamtin sales fell 26% to
£20 million as a result of generic competition in Europe.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind